Commonly used embolic particles and microspheres in TACE procedures are primarily designed to embolize tissues at the small artery and capillary level, achieving distal embolization. First-generation embolic materials have limitations such as predominantly distributing in proximal vessels, a high likelihood of recanalization, and significant inflammatory responses. PVA microspheres can significantly reduce inflammatory reactions, but many PVA microspheres present issues like large dimensional deformation, long drug-loading times, fragmentation after drug loading, and burst release, making it difficult to achieve long-term efficacy.China-produced Novel Bionic "Core-Shell" Embolic Microspheres, Utilizing Multiple Core Patent Technologies, Innovate Microsphere Structure, Bringing Significant Advancements in Microsphere Performance.

Conventional microspheres used in DEB-TACE treatments present challenges such as difficulty in determining the endpoint of embolization, assessing the distribution of embolic materials during the procedure, and unclear targets for subsequent sequential treatments (MDT). Visualizable microspheres can provide real-time feedback during the treatment process, enabling physicians to quickly evaluate the effectiveness of large tumor treatments, anticipate risks like cholecystitis in advance, and mark target points for ablation therapy.In a patient with malignant liver tumor, embolization treatment was performed using uniformly sized, visualized drug-loaded embolic microspheres produced in China. The microspheres showed clear visibility under DSA and CBCT, allowing for intraoperative assessment of whether ectopic embolization occurred and timely adjustments. This is of great significance for avoiding excessive embolization, pseudo-embolization, and achieving precise embolic margins.

TACE is one of the most widely recognized and commonly used local treatment methods for liver cancer, covering the treatment of TACE liver cancer patients from stage Ib to the end of stage III. Precision TACE is one of the important development directions of TACE. The development direction of precision super-selective catheter tools in precision TACE includes: ultra-fine microcatheters—application of 2.0F and below microcatheters can achieve super-selective catheterization to sub-subsegmental vessels; steerable microcatheters—designed for complex structural vessels that are difficult for ordinary microcatheters to access, enabling real-time intraoperative control of the tip for faster super-selective positioning; balloon microcatheters: balloon occlusion embolization (B-TACE)—altering local hemodynamics to generate pressure gradient-driven embolization (Pressure Gradient-Driven Embolization), preventing reflux, and increasing the deposition of embolic agents in the lesion area. Balloon occlusion hepatic arterial infusion chemotherapy (B-HAIC)—significantly reducing intrahepatic blood perfusion, further increasing the local drug concentration within the liver, prolonging the time chemotherapy drugs pass through the liver, enhancing the liver’s uptake of the drugs, and strengthening anti-tumor effects. Case 1 demonstrates,Using a steerable microcatheter,Achieve real-time precise control of the proximal to the distal end during the operation,Can effectively meet the super-selective needs of complex vascular structures。In the second case, the patient with liver tumor had blood supply from the subphrenic artery, which has pericardial branches. There was a significant shunt of drugs or embolic agents to the pericardium. The use of a balloon microcatheter for occlusion and embolization effectively prevented the reflux of embolic materials into the pericardium.Blood Supply Branch. Balloon Occlusion Embolization with Balloon Microcatheter, Injury.